文献速递哮喘

XALOC-1:本瑞利珠单抗治疗重度嗜酸性粒细胞性哮喘2年临床缓解

XALOC-1: Clinical Remission Over 2 Years With Benralizumab in Severe Eosinophilic Asthma.
PubMed 文献 · Chest · 2025-04-19

XALOC-1是一项多国回顾性真实世界研究,纳入1,070例接受本瑞利珠单抗治疗≤96周的重度嗜酸性粒细胞性哮喘成人患者。第48周和第96周分别有39%和31%的患者达到临床缓解复合标准(无急性发作、无维持口服糖皮质激素、哮喘良好控制)。基线维持口服糖皮质激素剂量较低、BMI较低和峰值嗜酸性粒细胞计数较高与第96周达到临床缓解正相关。

要点

  • 约三分之一重度嗜酸性粒细胞性哮喘患者接受本瑞利珠单抗治疗2年可达临床缓解。
  • 生物制剂初治患者第48周和第96周缓解率分别为43%和36%,经治患者分别为32%和23%。
  • 基线疾病负担较低者更易达到临床缓解,提示早期启动生物制剂可能获益。

核心结论

  • 临床缓解是接受本瑞利珠单抗治疗的重度嗜酸性粒细胞性哮喘患者的现实目标,约三分之一患者可维持至2年。
  • 基线疾病负担较低的患者更可能达到临床缓解,提示早期启动生物制剂可能有益,需进一步研究。

研究设计与样本

  • XALOC-1为多国、回顾性、真实世界研究,纳入接受本瑞利珠单抗治疗≤96周的成人重度嗜酸性粒细胞性哮喘患者1,070例。
  • 在第0、48和96周评估临床缓解各组分及复合标准的达标百分比,并在第48和96周采用多变量logistic回归分析基线特征与临床缓解的关联。

主要发现

  • 第0、48和96周分别有0.4%、39%和31%的患者满足3组分临床缓解标准。
  • 生物制剂初治和经治患者第48周缓解率分别为43%和32%,第96周分别为36%和23%。
  • 基线维持口服糖皮质激素剂量较低(OR 0.51;95%CI 0.34-0.76)、BMI较低(OR 0.56;95%CI 0.36-0.86)和峰值嗜酸性粒细胞计数较高(OR 1.68;95%CI 1.05-2.69)与第96周达到临床缓解正相关。

关键数值与推荐

  • 临床缓解复合标准:无急性发作、无维持口服糖皮质激素使用、哮喘良好控制(ACT评分≥20或ACQ-6评分≤0.75)。

临床怎么用

  • 本瑞利珠单抗治疗重度嗜酸性粒细胞性哮喘时,可将临床缓解作为长期管理目标,约三分之一患者2年可持续达标。
  • 基线维持口服糖皮质激素剂量较低、BMI较低和峰值嗜酸性粒细胞计数较高的患者更可能达到临床缓解,可据此评估获益概率。
  • 对基线疾病负担较低的重度嗜酸性粒细胞性哮喘患者,可考虑早期启动生物制剂以争取临床缓解。

局限性

  • 本研究为回顾性真实世界研究,未设对照组,可能存在选择偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term real-world data on clinical remission in patients with severe eosinophilic asthma (SEA) receiving biologics are lacking. We describe clinical remission over 2 years in patients with SEA receiving benralizumab. RESEARCH QUESTION: Is long-term clinical remission a viable goal for patients with SEA receiving benralizumab? STUDY DESIGN AND METHODS: XALOC-1 is a multinational, retrospective, real-world program in adults with SEA who received benralizumab for ≤ 96 weeks. Percentages of patients meeting the components and composite of clinical remission (no exacerbations, no maintenance oral corticosteroid use, and well-controlled asthma [Asthma Control Test score ≥ 20 or 6-item Asthma Control Questionnaire score ≤ 0.75]) were assessed at weeks 0, 48, and 96. The association between key baseline demographics, clinical characteristics, and clinical remission status was assessed at weeks 48 and 96 using multivariable logistic regression analysis. RESULTS: Of 1,070 patients, 0.4%, 39%, and 31% met the 3-component clinical remission criteria at weeks 0, 48, and 96, respectively. In biologic-naive and biologic-experienced patients, remission occurred in 43% and 32% (week 48), and 36% and 23% (week 96), of patients, respectively. Lower maintenance oral corticosteroid dose (OR, 0.51; 95% CI, 0.34-0.76), lower BMI (OR, 0.56; 95% CI, 0.36-0.86), and higher peak eosinophil count (OR, 1.68; 95% CI, 1.05-2.69) at baseline were positively associated with meeting criteria for clinical remission at week 96. INTERPRETATION: Our results indicate that clinical remission is a realistic goal, sustainable up to 2 years in around one-third of patients with SEA receiving benralizumab. In this study, remission was more likely in patients with lower baseline disease burden, suggesting that further research is warranted regarding whether earlier initiation of a biologic may be beneficial.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Pelaia G, Jackson DJ, Nair P, et al. XALOC-1: Clinical Remission Over 2 Years With Benralizumab in Severe Eosinophilic Asthma. Chest. 2025. PMID: 40258512. doi:10.1016/j.chest.2025.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。